vs
REPUBLIC BANCORP INC（RBCAA）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
REPUBLIC BANCORP INC的季度营收约是RIGEL PHARMACEUTICALS INC的1.4倍（$94.3M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 24.2%，领先359.8%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 5.3%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -11.5%）
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
RBCAA vs RIGL — 直观对比
营收规模更大
RBCAA
是对方的1.4倍
$69.8M
营收增速更快
RIGL
高出15.9%
5.3%
净利率更高
RIGL
高出359.8%
24.2%
两年增速更快
RIGL
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.3M | $69.8M |
| 净利润 | $22.8M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 29.3% | 33.2% |
| 净利率 | 24.2% | 384.0% |
| 营收同比 | 5.3% | 21.2% |
| 净利润同比 | 20.0% | 1769.2% |
| 每股收益（稀释后） | — | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RBCAARIGL
| Q4 25 | $94.3M | $69.8M | ||
| Q3 25 | $93.5M | $69.5M | ||
| Q2 25 | $93.8M | $101.7M | ||
| Q1 25 | $135.8M | $53.3M | ||
| Q4 24 | $89.5M | $57.6M | ||
| Q3 24 | $88.1M | $55.3M | ||
| Q2 24 | $86.9M | $36.8M | ||
| Q1 24 | $120.3M | $29.5M |
净利润RBCAARIGL
| Q4 25 | $22.8M | $268.1M | ||
| Q3 25 | $29.7M | $27.9M | ||
| Q2 25 | $31.5M | $59.6M | ||
| Q1 25 | $47.3M | $11.4M | ||
| Q4 24 | $19.0M | $14.3M | ||
| Q3 24 | $26.5M | $12.4M | ||
| Q2 24 | $25.2M | $-1.0M | ||
| Q1 24 | $30.6M | $-8.2M |
毛利率RBCAARIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率RBCAARIGL
| Q4 25 | 29.3% | 33.2% | ||
| Q3 25 | 40.4% | 40.9% | ||
| Q2 25 | 43.0% | 60.1% | ||
| Q1 25 | 44.1% | 23.9% | ||
| Q4 24 | 25.8% | 28.9% | ||
| Q3 24 | 38.4% | 25.4% | ||
| Q2 24 | 37.0% | 1.2% | ||
| Q1 24 | 32.2% | -23.6% |
净利率RBCAARIGL
| Q4 25 | 24.2% | 384.0% | ||
| Q3 25 | 31.8% | 40.2% | ||
| Q2 25 | 33.5% | 58.6% | ||
| Q1 25 | 34.8% | 21.5% | ||
| Q4 24 | 21.2% | 24.9% | ||
| Q3 24 | 30.1% | 22.5% | ||
| Q2 24 | 29.0% | -2.8% | ||
| Q1 24 | 25.4% | -27.9% |
每股收益（稀释后）RBCAARIGL
| Q4 25 | — | $14.11 | ||
| Q3 25 | — | $1.46 | ||
| Q2 25 | — | $3.28 | ||
| Q1 25 | — | $0.63 | ||
| Q4 24 | — | $0.82 | ||
| Q3 24 | — | $0.70 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | — | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $220.0M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $1.1B | $391.5M |
| 总资产 | $7.0B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资RBCAARIGL
| Q4 25 | $220.0M | $155.0M | ||
| Q3 25 | $484.2M | $137.1M | ||
| Q2 25 | $484.8M | $108.4M | ||
| Q1 25 | $793.0M | $77.1M | ||
| Q4 24 | $432.2M | $77.3M | ||
| Q3 24 | $530.9M | $61.1M | ||
| Q2 24 | $400.1M | $49.1M | ||
| Q1 24 | $546.4M | $49.5M |
总债务RBCAARIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益RBCAARIGL
| Q4 25 | $1.1B | $391.5M | ||
| Q3 25 | $1.1B | $117.6M | ||
| Q2 25 | $1.1B | $81.9M | ||
| Q1 25 | $1.0B | $18.6M | ||
| Q4 24 | $992.0M | $3.3M | ||
| Q3 24 | $979.7M | $-14.6M | ||
| Q2 24 | $955.4M | $-29.9M | ||
| Q1 24 | $935.6M | $-31.7M |
总资产RBCAARIGL
| Q4 25 | $7.0B | $513.6M | ||
| Q3 25 | $7.0B | $242.5M | ||
| Q2 25 | $7.0B | $206.7M | ||
| Q1 25 | $7.1B | $176.0M | ||
| Q4 24 | $6.8B | $164.0M | ||
| Q3 24 | $6.7B | $139.4M | ||
| Q2 24 | $6.6B | $128.4M | ||
| Q1 24 | $6.9B | $126.5M |
负债/权益比RBCAARIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $168.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $161.1M | — |
| 自由现金流率自由现金流/营收 | 170.9% | — |
| 资本支出强度资本支出/营收 | 7.5% | — |
| 现金转化率经营现金流/净利润 | 7.37× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $288.6M | — |
8季度趋势，按日历期对齐
经营现金流RBCAARIGL
| Q4 25 | $168.2M | $22.0M | ||
| Q3 25 | $33.3M | $24.0M | ||
| Q2 25 | $8.4M | $30.5M | ||
| Q1 25 | $93.2M | $-893.0K | ||
| Q4 24 | $149.0M | $14.5M | ||
| Q3 24 | $51.3M | $21.7M | ||
| Q2 24 | $4.0M | $302.0K | ||
| Q1 24 | $71.2M | $-5.0M |
自由现金流RBCAARIGL
| Q4 25 | $161.1M | — | ||
| Q3 25 | $30.8M | — | ||
| Q2 25 | $5.2M | — | ||
| Q1 25 | $91.6M | — | ||
| Q4 24 | $143.2M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $2.7M | — | ||
| Q1 24 | $69.1M | — |
自由现金流率RBCAARIGL
| Q4 25 | 170.9% | — | ||
| Q3 25 | 32.9% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | 67.4% | — | ||
| Q4 24 | 160.0% | — | ||
| Q3 24 | 56.5% | — | ||
| Q2 24 | 3.1% | — | ||
| Q1 24 | 57.5% | — |
资本支出强度RBCAARIGL
| Q4 25 | 7.5% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 6.5% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.7% | — |
现金转化率RBCAARIGL
| Q4 25 | 7.37× | 0.08× | ||
| Q3 25 | 1.12× | 0.86× | ||
| Q2 25 | 0.27× | 0.51× | ||
| Q1 25 | 1.97× | -0.08× | ||
| Q4 24 | 7.84× | 1.01× | ||
| Q3 24 | 1.93× | 1.75× | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 2.33× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
